Mandos is a biopharmaceutical company committed to furthering development of adrabetadex* for Niemann-Pick Type C. The company is led by a diverse and passionate management team experienced in every stage of the drug development process from research through commercialization.
Please find a link to the September communication from Mandos, LLC.